Research on maintenance treatment to prevent relapse of psychotic disorders

Abstract

<p>The issue of <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/typical-antipsychotic" title="Learn more about antipsychotic from ScienceDirect's AI-generated Topic Pages">antipsychotic</a> (dis)continuation has been a long-standing clinical dilemma. While the routine usage of antipsychotic is associated with side effects and stigma, short-term evidence suggest that the risk of relapse is heightened following antipsychotics withdrawal. Clinical guidelines therefore propose a one to two years duration of maintenance treatment upon remission in first episode psychosis (FEP), but guidance beyond which remains unclear. Only two controlled studies have addressed the long-term consequences of antipsychotic discontinuation. While Wunderink et al. concluded that <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/drug-dose-reduction" title="Learn more about dose reduction from ScienceDirect's AI-generated Topic Pages">dose reduction</a> is associated with a higher rate of recovery, Hui et al. found discontinuation to be associated with better clinical outcomes. Data from Hui et al.’s study further suggests that treatment should be maintained for at least the first three years upon remission in FEP in order reduce the risk of relapse, as well as subsequent poor long-term outcome. It is noted that the two studies not only differ in outcome measures, but also in their strategies of “antipsychotic discontinuation”. Considering that discontinuation is a more compelling option to most patients, it may therefore be more clinically relevant. More long-term follow-up discontinuation studies are needed to provide further evidence in the development of treatment guidelines for FEP.<br></p>